|Back to News|
Santa Clara, CA, September 1, 2009 — Cell Biosciences, Inc. today launched a service program to provide phosphoprotein analysis of pre-clinical samples for pharmaceutical and biotechnology companies. Under the Cell Biosciences Focus Assay Service program, client companies receive detailed analytical information about cell signaling proteins in their specimens. This information provides insight into disease processes and aids in the development of new treatments. The service will be performed using the Cell Biosciences CB1000 system, which enables quick and quantitative analysis of critical control proteins in extremely small samples - as few as 25 cells per measurement.
“The Focus Assay Service was developed in direct response to customer needs,” said Dr. Wilhelm Lachnit, Vice President of R&D and Applications at Cell Biosciences. “Since the April launch of the CB1000 system, we've received numerous requests for an analytical service offering. This technology has clearly captured the interest of researchers and we're excited to share it with more customers.”
The Focus Assay Service presently features a menu of assays for proteins involved in cancer cell growth and proliferation. A custom assay development service is available for novel proteins. Each Focus project includes a dedicated project manager who directs the study from sample preparation to final presentation. “We've designed every aspect of the Focus Assay Service with the customer in mind,” continued Dr. Lachnit. “This program represents a fast, affordable way to access the CB1000 technology.”
About Cell Biosciences
Cell Biosciences is a private life sciences company focused on nanoproteomics. We develop instrumentation systems, software, and assay products that reveal previously undetectable information about cellular control pathways. Our customers include leading institutions in the fields of cancer research, stem cell biology, and diabetes. Our products enable researchers to uncover fundamental mechanisms controlling cell proliferation and cell death, to accelerate the development of new therapeutics, and to help identify new prognostic and diagnostic disease biomarkers. Cell Biosciences is located in Santa Clara, California. For more information, visit www.cellbiosciences.com.
CONTACT: Jocelyn Davé, Product Manager, Cell Biosciences, Inc., (408) 510-5513, email@example.com.